The Asia Oceania Congress of Nuclear Medicine and Biology
The Asia Oceania Congress of Nuclear Medicine and Biology
The Asia Oceania Congress of Nuclear Medicine and Biology
The Asia Oceania Congress of Nuclear Medicine and Biology

The Asia Oceania Congress of Nuclear Medicine and Biology-Molecular Imaging, Imaging your Mind-

Sept 6th – 7th, 2022 Kyoto, Japan | ONLINE-ONSITE-Hybrid

flier

  • The 14th AOCNMB 2022
  • The 7th AONMAF
  • The 5th CIS
  • The 2th EANMA
  • Sino-Japanese Association for Nuclear Medicine Intercommunion

Call for abstracts for AONMAF, CIS, EANMA, and S-J is open.

Abstract Submission

President's Message

Gang Huang Prof., MD AOFNMB President
Gang Huang Prof., MDAOFNMB President

Dear professors and colleagues of Nuclear Medicine.

The 14th Asia Oceania Congress of Nuclear Medicine and Biology will be conducted from 6-7 September 2022 in Kyoto, Japan. The theme of this year is "Molecular Imaging, Imagining your Mind", the main objective of this Congress is to strengthen the development and clinical application in the field of Molecular Imaging in Asia and Oceania. Despite the global impact of COVID 19 pandemic, I’m excited that the conference could be held online and offline after three years. We will not only share the most updated technology of nuclear medicine but also improve our network and understanding of each other. I wish for a very successful event at the 14th Asia Oceania Congress of Nuclear Medicine and Biology!

Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB) is a regional organization of nuclear medicine with a long history. Since established in Tokyo in October 1969, 13 conferences were conducted with a tremendous contribution to the development of nuclear medicine in both Asia and Oceania. AOFNMB has been well recognized all round the world and the Federation has worked together very closely with International Atomic Energy Agency, World Congress of Nuclear Medicine, American Society of Nuclear Medicine, European Association of Nuclear Medicine, etc. to improve the technology of nuclear medicine worldwide. We believe that the 14th AOCNMB Conference will not only build on the success of the past but also provide academic highlights and enhance our friendship as well as deepen our mutual understanding.

The 14th AOCNMB provides a great platform for exchanging and sharing diversified culture and multiple ideas and scientific point of view. I hope that all the colleagues could actively participate in the Congress and share your experience and innovative achievements with each other. Also, I sincerely hope that different medical instrument companies could also participate in the Congress and get to know each other. Let’s all enjoy this conference and work together for the development of AOCNMB to reach the next milestone.

In the end, I wish all experts and representatives of related manufacturers good health and I look forward to meeting all of you in Kyoto, Japan, a city of beauty and historical origin.

Gang Huang Prof., MDAOFNMB President
Signature of Gang Huang

Plenary Session

Sept.6, 2022 8:45-10:15

Moderator
Yaming Li (China Medical University)
Hiroshi Matsuda (Fukushima Medical University)

Key note Lecture 1

Xiaofeng Li

Xiao-Feng Li

Department of Nuclear Medicine, Shenzhen People's Hospital, Shenzhen (China)

CV
Education (with year of graduation)
  • Bachelor of Medicine (M.B.) Norman Bethune University of Medical Sciences (Changchun, China) 1993
  • Ph.D. in medical sciences with honor, Kanazawa University (Kanazawa, Japan) 2003
  • Doctor of Medicine (M.D.) The University of the State of New York (Albany NY, USA) 2018
  • Fellow, Memorial Sloan-Kettering Cancer Center, New York NY, USA 2009
Professional Career (with duration)
  • 1993-1998 Assistant Professor & assistant attending, Department of Nuclear Medicine, The Second Affiliated Hospital of Harbin Medical University (Harbin China)
  • 1998-2003 Teaching and research assistant, Kanazawa University (kanazawa Japan)
  • 2003-2008 Research fellow, Memorial Sloan-Kettering Cancer Center (New York NY)
  • 2008-2009 Research associate, Memorial Sloan-Kettering Cancer Center (New York NY)
  • 2009-2017 From Assistant professor to clinical professor, Department of Radiology University of Louisville (Louisville KY)
  • 2017-2018 Chairman and chief attending, Department of Nuclear Medicine, Shenzhen Hospital of Southern Medical University (Shenzhen China)
  • 2018-current Chairman and chief attending, Department of Nuclear Medicine, Shenzhen People's Hospital
    The Second Clinical Medical College, Jinan University, and The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China
Publications in 5 years
  1. Li J, Zhang G, Wang X and Li XF*. Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia? Future Oncology. 2015 May;11(10):1531-41
  2. Cui YL, Wang X, Li XF*. (18)F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer. Future Oncol. 2015;11(20):2841-9. doi: 10.2217/fon.15.205. Epub 2015 Sep 11. PubMed PMID: 26361064.
  3. Zhang Q, Du Y, Jing L, Liang X, Li Y, Jia X, Li XF, Dai Z and Tian J. IRDye-800CW Conjugated Endostar-loaded PLA Nanoparticles Operate as a Novel Theranostic Nanomedicine for Breast Cancer. Journal of biomedical nanotechnology 2016 Mar;12(3):491-502
  4. Russell J, Tian J, Kinuya S, Shen B and Li XF*. Editorial: Molecular imaging plays critical role for personalized medicine. BioMed Research Int. 2016 June; 2016:5170159. doi: 10.1155/2016/5170159. Epub 2016 Aug 29
  5. Wu Y, Zhang G, Wang X, Zhao Z, Wang T, Wang X and Li XF*. Early detection of rheumatoid arthritis in rats and humans with 99mTc-3PRGD2 scintigraphy: Imaging synovial neoangiogenesis. Oncotarget. 2017;8:5753-5760.
  6. Wang X, He Y, Zhou W, Bai X, Wang X, Wu Y, and Li XF. Mismatched Intratumoral Distribution of 18F-Fluorodeoxyglucose and 3'-Deoxy-3'-18F-Fluorothymidine in Lung Cancer of Patients. Oncology Letters 2017;14:5279-5284.
  7. Li Y, Wang Q, Wang X, Li X, Wu H, Wang Q, Yao Z, Miao W, Zhu X, Hua F, Zhang X, Cheng C, Zhang W, Hou Q, Li Y, and Li XF. Expert Consensus on clinical application of FDG PET/CT in infection and inflammation. ANN NUCL MED. 2020 May;34(5):369-376.
  8. Li Y, Zhao L and Li XF*. The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy. FRONTIERS IN PHARMACOLOGY 2021 Apr 19;12:636892. doi: 10.3389/fphar.2021.636892. eCollection 2021.
  9. Yao Y, Li YM, He ZX, Civelek AC and Li XF*. Likely Common Role of Hypoxia in Driving 18F-FDG Uptake in Cancer, Myocardial Ischemia, Inflammation and Infection, Cancer Biotherapy & Radiopharmaceuticals 2021 Oct;36(8):624-631
  10. Li Y, Zhao L, Li XF* Hypoxia and the Tumor Microenvironment. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036304. doi: 10.1177/15330338211036304.
  11. Li Y, Zhao L, Li XF*. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy. Front Oncol. 2021 Jul 29;11:700407. doi: 10.3389/fonc.2021.700407. eCollection 2021.
Post-Pandemic Nuclear Medicine Practice is still Focusing on 18F-FDG PET
Summary of Speech
In 1976, the first human 18F-fluorodeoxyglucose (18F-FDG) imaging was performed to image the health brain in USA; 18F-FDG positron emission tomography (PET) has become an important tool for detection, staging and management of many types of cancer since 1990s. In next decade or two, I believe that 18F-FDG is still playing a key PET for routine oncology practice. Pasteur effect, Warburg effect and reverse Warburg effect have been used to explain glucose metabolism in cancer. In animal models of cancer, we have demonstrated that 18F-FDG avidly accumulates in poorly proliferating and hypoxic cancer cells, but low in well perfused (and proliferating) cancer cells, stroma and necrosis, therefore,18F-FDG is hypoxia-avid PET tracer, not a cancer-specific tracer (J Nucl Med 2010;51:632-8,J Nucl Med 2012; 53:1262–1268, Translational Oncology 2014;7:240-247,J Nucl Med 2015; 56:607–612). 18F-FDG PET routinely uses on oncology; 95% solid malignancy presents hypoxia. We have explored that increased 18F-FDG uptake in ischemic myocardium, infection/inflammation would also be explained by the presence of hypoxia (Cancer Biother Radiopharm. 2021;36:624-631), which explains why 18F-FDG-avid infection/inflammation and malignancies are sometimes difficult to be distinguished clinically, on the other hand, some cancer are non-18F-FDG-avid to be visualized by PET alone, such as, those malignancies have not presented hypoxia. Clinically we have demonstrated the pattern “exclusion of blood perfusion and glucose metabolism in a pilot dual-phase 18F-FDG PET patients study, and concluded intratumoral 18F-FDG accumulation and 18F-FDG “vascular-nuclear-graphy” are mutually exclusive in patients with lung cancer (OncoTarget 2017;27;8:43536-43542) and HCC (SNMMI 2019). In conclusion, 18F-FDG18F-FDG highly accumulation in hypoxic and poorly proliferating cancer cells, 18F-FDG is not a cancer specific PET tracer. Revisiting18F-FDG uptake mechanism may promote cancer care.

Key note Lecture 2

Akram Al-Ibraheem

Akram Al-Ibraheem

King Hussein Cancer Center, Amman (Jordan)

CV
Education (with year of graduation)
  • 1992-1995: High school and Tawjihi exam (Excellent average).
  • 1995–2001: BACHELOR of DCTOR in MEDICINE (Good Average), Faculty of Medicine, Aleppo University, Aleppo – Syria.
  • 2003-2007: Residency program of Nuclear Medicine, JRMS.
  • 2008-2009: Fellowship of PET/CT & Nuclear Oncology, Munich University Technology (TUM), Germany.
Professional Career (with duration)
  • 2008-2009: Fellowship of PET/CT & Nuclear Oncology, Klinikum rechts der Isar, Technische Universität München, Munich-Germany. (Mentor; Prof. Markus Schwaiger).
  • 10/2009-1/2011: Attending Staff, Royal Medical Services, Amman- Jordan.
  • 2011-till now: Chairman of Nuclear Medicine Department (KHCC).
  • 2015-till now: Consultant Faculty, Nuclear Medicine (Part-time) Jordan University Hospital, Amman, Jordan.
  • 2019-till now: Clinical Associate Professor, School of Medicine, Jordan University
Publications in 5 years
  • 68Ga-DOTATOC Embolus Manifestation and Spontaneous Resolution by PET/CT 2022, Akram Al-Ibraheem, Deya Sweedat, Farah Anwer, Nuclear Medicine and Molecular Imaging.
  • Challenging Results on FDG PET/CT in a Patient with Uncontrolled Celiac Disease and small bowel adenocarcinoma A Mohamedkhair, A Al-Ibraheem, AS Abdlkadir… - Asia Oceania Journal of Nuclear Medicine and Biology, 2022
  • Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)JJ Cerci, S Fanti, EE Lobato, J Kunikowska, O Alonso… - Journal of Nuclear Medicine, 2022.
  • The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy: real-world data, H Abdel-Razeq, U Al-Rasheed, N Mashhadani… - Irish Journal of Medical Science (1971-), 2022
  • Anal cancer with isolated ischial fossa lymph node metastases: A rare entity in the oligometastatic dilemma, I Mohamad, R Abuhijlih, M Alkaldi, A Al-Ibraheem… - 2022.
  • Renal spindle cell tumor with thrombus extension into the inferior vena cava and the right atrium depicted by positron emission tomography/computerized tomography scan . NQA Deya'Aldeen Sweedat, JK Hajaj, AI Akram - 2022
  • Bone Scan in Identification, Assessment of Initial Extent and Response to Therapy in Polymyositis, ME Juweid, N Mashhadani, OM Albtoush, R Doudeen… - Asia Oceania Journal of Nuclear Medicine and Biology, 2022
  • Impact of COVID-19 on nuclear medicine in Asia HSH Bom, TNB Pascual, PS Choudhury… - Seminars in Nuclear Medicine, 2022
  • Metabolic and functional imaging employment in the differentiation of brown tumors from bone metastases in a case of primary papillary thyroid cancer and parathyroid adenoma: case report. U Al-Rasheed, F Barakat, A Al-Ibraheem - Journal of the Egyptian National Cancer Institute, 2021.
  • Impact of 18 F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC. 2021. A Al-Ibraheem, N Hirmas, S Fanti, D Paez, F Abuhijla, D Al-Rimawi, ... BMC medical imaging 21 (1), 1-9 https://doi.org/10.1186/s12880-021-00580-w ((Corresponding & First Author)
  • The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy. 2021A Al-Ibraheem, F Abuhijla, S Salah, M Shahait, J Khader, I Mohamad. Nuclear Medicine Communications DOI: 10.1097/MNM.0000000000001394 ((First Author)
  • Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study). Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, Novruzov F, Lengana T, Granados C, Kumar R, Rangarajan V, Al-Ibraheem A, Hourani M, Ali NS, Ahmad A, Keidar Z, Küçük O, Elboga U, Bogoni M, Paez D. J Nucl Med. 2022 Feb;63(2):240-247. doi: 10.2967/jnumed.120.261886. Epub 2021 Jul 2. PMID: 34215674; PMCID: PMC8805782.
  • The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy: real-world data. Abdel-Razeq H, Al-Rasheed U, Mashhadani N, Al-Ibraheem A, Abdel-Razeq R, Jaradeh SA, Mansour R, Bater R, Tbayshat S. Ir J Med Sci. 2022 Jan 28. doi: 10.1007/s11845-021-02897-5. Epub ahead of print. PMID: 35088228.
  • Challenging Results on FDG PET/CT in a Patient with Uncontrolled Celiac Disease and Small Bowel Adenocarcinoma. Mohamedkhair, A., Al-ibraheem, A., Abdlkadir, A., Jaber, O. Asia Oceania Journal of Nuclear Medicine and Biology, 2022; (): -. doi: 10.22038/aojnmb.2022.61853.1437Biology (Corresponding author)
  • Al-Rasheed U, Barakat F, Al-Ibraheem A. Metabolic and functional imaging employment in the differentiation of brown tumors from bone metastases in a case of primary papillary thyroid cancer and parathyroid adenoma: case report. J Egypt Natl Canc Inst. 2021 Oct 18;33(1):30. doi: 10.1186/s43046-021-00089-x. PMID: 34657985. (Corresponding author)
  • Juweid ME, Mashhadani N, Albtoush OM, Doudeen R, Al-Momani A, Aloqaily M, Al-Ibraheem A. Bone Scan in Identification, Assessment of Initial Extent and Response to Therapy in Polymyositis. Asia Ocean J Nucl Med Biol. 2022 Winter;10(1):64-67. doi: 10.22038/AOJNMB.2021.57818.1403. PMID: 35083353; PMCID: PMC8742850.
  • Impact of COVID-19 on nuclear medicine in Asia. 2021 HSH Bom, TNB Pascual, PS Choudhury, A Al-Ibraheem Seminars in Nuclear Medicine. DOI: 10.1053/j.semnuclmed.2021.06.001
  • Metabolic and functional imaging employment in the differentiation of brown tumors from bone metastases in a case of primary papillary thyroid cancer and parathyroid adenoma. 2021
  • U Al-Rasheed, F Barakat, A Al-Ibraheem, Journal of the Egyptian National Cancer Institute 33 (1), 1-8, PMID: 34657985 DOI: 10.1186/s43046-021-00089-x (Corresponding author)
  • 68 Ga DOTA-TOC Uptake in Non-ossifying Fibroma: a Case Report. 2020 A Khalaf, N Hirmas, F Anwer, A Al-Ibraheem Nuclear Medicine and Molecular Imaging 54 (4), 199-203 (Corresponding Author)
  • [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.Hirmas N, Al-Ibraheem A, Herrmann K, Alsharif A, Muhsin H, Khader J, Al-Daghmin A, Salah SMol Imaging Biol. 2018 Sep 13. doi: 10.1007/s11307-018-1278-8. [Epub ahead of print]PMID:30215174 (Corresponding Author)
  • Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low-and middle-income countries: preliminary results from the IAEA PERTAIN trial European journal of nuclear medicine and molecular imaging 46 (11), 2235-2243
  • Current Status of Theranostics in Jordan. Nucl Med Mol Imaging. 2019 Feb;53(1):7-10. doi: 10.1007/s13139-018-0562-5. ((Corresponding & First Author)
  • Metastatic pulmonary adenocarcinoma to the nasopharynx at first clinical presentation: A case report and review of literature S Iqneibi, J Nazzal, R Amoudi, B Owda, A Al-Ibraheem, S Yaser, ...SAGE Open Medical Case Reports 8, 2050313X20939826
  • Clinico-social factors to choose radioactive iodine dose in differentiated thyroid cancer patients: an Asian survey Nucl Med Commun. 2018 Apr;39(4):283-289. doi: 10.1097/MNM.0000000000000804 Thyroid Study Group of the Asia Oceania Research Initiative Network (AORIN).
  • Clinical Impact of 18F-FDG PET/CT on the Management of Gynecologic Cancers: One Center Experience. Asia Ocean J Nucl Med Biol. 2019 Winter;7(1):7-12. doi: 10.22038/AOJNMB.2018. ((Corresponding & First Author).
  • Case report of epithelioid osteoblastoma of the mandible: findings on positron emission tomography/computed tomography and review of the literature. Al-Ibraheem A, Yacoub B, Barakat A, Dergham MY, Maroun G, Haddad H, Saleh A, Khoury N, Hourani M, Haidar MB. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Dec 31.
  • Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives, 2018. Nuclear Medicine and Molecular Imaging doi.org/10.1007/s13139-018-0517-x (Corresponding Author)
  • 68 Ga DOTA-TOC Uptake in Non-ossifying Fibroma: a Case Report A Khalaf, N Hirmas, F Anwer, A Al-Ibraheem Nuclear Medicine and Molecular Imaging 54 (4), 199-203 (Corresponding Author)
  • Metastatic pulmonary adenocarcinoma to the nasopharynx at first clinical presentation: A case report and review of literatureS Iqneibi, J Nazzal, R Amoudi, B Owda, A Al-Ibraheem, S Yaser, SAGE Open Medical Case Reports 8, 2050313X20939826
  • Impact of interim FDG PET/CT on Hodgkin Lymphoma adult patients at King Hussein Cancer Center (KHCC), Jordan. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING SUPPL 1 S370-S371 (Corresponding Author) 2020.
  • Assessment of segmental left ventricular thickening in diabetic type II obese patients with normal myocardial perfusion scan 2017. Hell J Nucl Med. 2017 Sep-Dec;20(3):222-226. doi: 10.1967/s002449910603. Epub 2017 Nov 27.
  • Clinical impact of 18F-FDG PET/CT on the management of gynecologic cancers: One center experience. Asia Ocean J Nucl Med Biol. 2018 (First Author).
Nuclear Medicine is Revolutionizing; Despite the Pandemic
Summary of Speech
The landscape for Nuclear Medicine is undergoing a major transformation in the last decade. The main drivers are molecular imaging and the emergence of Theranostics. COVID-19 pandemic has changed many aspects of our health care practice. This includes the clinical approach, education, research, and industry. Nuclear medicine, like other specialties, has had its share of these pandemic-related difficulties. Travel restriction has obstructed the move of the radiopharmaceuticals which are considered the backbone of nuclear medicine. However, nuclear medicine communities across the globe have exercised all possible efforts to provide solutions. Furthermore, nuclear medicine leaders have found ways to thrive despite the difficulties. Taking the advantage of the progress which has been achieved in the last decade by introducing a more specific molecular target, and expanding theranostics applications. On the other hand, the innovation in the nuclear medicine industry has enabled the most precise imaging approach to empower personalized medicine.